Serotype Distribution and Disease Severity in Adults Hospitalized with Streptococcus pneumoniae Infection, Bristol and Bath, UK, 2006‒2022

Ongoing surveillance after pneumococcal conjugate vaccination (PCV) deployment is essential to inform policy decisions and monitor serotype replacement. We report serotype and disease severity trends in 3,719 adults hospitalized for pneumococcal disease in Bristol and Bath, United Kingdom, during 20...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2023-10, Vol.29 (10), p.1953-1964
Main Authors: Hyams, Catherine, Challen, Robert, Hettle, David, Amin-Chowdhury, Zahin, Grimes, Charli, Ruffino, Gabriella, Conway, Rauri, Heath, Robyn, North, Paul, Malin, Adam, Maskeli, Nick A, Williams, Philip, Williams, O. Martin, Ladhani, Shamez N, Danon, Leon, Finn, Adam
Format: Article
Language:English
Subjects:
Adults
Age
bacteria
Bacterial infections
Bacterial pneumonia
Care and treatment
CME
Cohort analysis
COVID-19 vaccines
Diagnosis
Disease transmission
Epidemics
Evaluation
Fatalities
Hospitals
Immunization
Infection, Bristol and Bath, UK, 2006‒2022
Laboratories
Mortality
Older people
Pandemics
Patients
pneumococcus
Pneumonia
serotype distribution
Serotype Distribution and Disease Severity in Adults Hospitalized with
serotypes
Streptococcus infections
Streptococcus pneumoniae
Surveillance
Time series
Trends
United Kingdom
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ongoing surveillance after pneumococcal conjugate vaccination (PCV) deployment is essential to inform policy decisions and monitor serotype replacement. We report serotype and disease severity trends in 3,719 adults hospitalized for pneumococcal disease in Bristol and Bath, United Kingdom, during 2006–2022. Of those cases, 1,686 were invasive pneumococcal disease (IPD); 1,501 (89.0%) had a known serotype. IPD decreased during the early COVID-19 pandemic but during 2022 gradually returned to prepandemic levels. Disease severity changed throughout this period: CURB65 severity scores and inpatient deaths decreased and ICU admissions increased. PCV7 and PCV13 serotype IPD decreased from 2006–2009 to 2021–2022. However, residual PCV13 serotype IPD remained, representing 21.7% of 2021–2022 cases, indicating that major adult PCV serotype disease still occurs despite 17 years of pediatric PCV use. Percentages of serotype 3 and 8 IPD increased, and 19F and 19A reemerged. In 2020–2022, a total of 68.2% IPD cases were potentially covered by PCV20.
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2910.230519